GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Dividend-Payout-to-FFO

Galapagos NV (Galapagos NV) Dividend-Payout-to-FFO


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.